Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Olmos, R. A. V.
Right arrow Articles by Hoefnagel, C. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Olmos, R. A. V.
Right arrow Articles by Hoefnagel, C. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 5:617-622, 1994
© 1994 European Society for Medical Oncology

research-article

Usefulness of indium-111 antimyosin scintigraphy in confirming myocardial injury in patients with anthracycline-associated left ventricular dysfunction

R. A. Valdés Olmos1,, W. W. ten Bokkel Huinink2, R. F. A. ten Hoeve1, H. van Tinteren3, P. F. Bruning2, B. van Vlies4 and C. A. Hoefnagel1

1Department of Nuclear Medicine, Netherlands Cancer Institute Amsterdam, The Netherlands
2Department of Medical Oncology, Netherlands Cancer Institute Amsterdam, The Netherlands
3Department of Biometrics, Netherlands Cancer Institute Amsterdam, The Netherlands
4Cardiology of the Academic Medical Center Amsterdam, The Netherlands

Correspondence to: R. A. Valdés Olmos, M.D., Dept. of Nuclear Medicine, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands

BACKGROUND:: In patients with cardiac dysfunction due to anthracycline-induced myocyte damage, continuation of anthracyclines carries a high risk, and modification of chemotherapy is thus indicated. The condition, however, must be distinguished from other causes of cardiac dysfunction, e.g., the transient negative inotropic effect which may accompany and follow the intravenous administration of anthracyclines. In the present study the efficacy of 111In-antimyosin in confirming myocyte injury and its potential applicability in differentiating causes of cardiac dysfunction during anthracy-cline therapy are evaluated.

PATIENTS AND METHODS:: Twenty-seven patients with asymptomatic left ventricle ejection fraction (LVEF) decrease (median LVEF 47%, range 38%–50%) during chemotherapy with anthracyclines (dose range 100–700 mg/m2 doxorubi-cin or equivalent) were subsequently studied with 111In-antimyosin cardiac scintigraphy. The degree of myocardial uptake, an indicator of heart muscle cell injury, evaluated both visually and quantitatively by means of heart-to-lung ratios (HLR) obtained from 48-hour planar images, was analyzed in relation to the further clinical and LVEF course. The results were also compared with 111In-antimyosin data from 5 patients wo had normal LVEF during chemotherapy and 5 patients who had received no anthracyclines. The distribution pattern of myocardial uptake was assessed by means of single photon emission computed tomography (SPECT).

RESULTS:: a) Fourteen patients presented with persistent LVEF decrease (median LVEF 42.5%, range 32%–47%) after discontinuation of anthracycline therapy. In 11 of these patients intense and diffuse, as shown by SPECT, cardiac uptake of 111In-antimyosin (HLR 1.87–2.45) was observed. In two patients with intense antimyosin cardiac uptake, spurious HLR values (1.23–1.55) were found which were caused by unexpected lung uptake and focal heart uptake, respectively. All patients with intense cardiac 111In-antimyosin uptake showed persistently decreased LVEF on follow-up (4–26 weeks) and 4 of them subsequently developed congestive heart failure. In another patient with no intense uptake (HLR 1.15) and persistent decrease in LVEF, metastatic cardiac involvement was found, b) In 13 patients with improvement or normalisation of the LVEF (median LVEF 53%, range 51%–63%), generally less intense or slight cardiac uptake (HLR range: 1.20–1.88) was seen; the HLR in these patients, who continued chemotherapy without complication was consistently lower (p <0.01) than in patients with persistently decreased LVEF, and comparable to values of patients who had normal LVEF.

CONCLUSIONS:: 111In-antimyosin scintigraphy can be useful to differentiate cardiac dysfunction caused by severe myocardial injury from temporary decreases in LVEF, without severe concomitant myocyte damage, which may occur during anthracycline therapy. Intense myocardial uptake of 111In-antimyosin can be used as an important confirmatory criterium for the clinical decision to discontinue anthracycline therapy.

111In-antimyosin, myocyte injury, anthracycline cardiotoxicity


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
I. Goethals, O. De Winter, P. De Bondt, J. De Sutter, R. Dierckx, and C. Van De Wiele
The clinical value of nuclear medicine in the assessment of irradiation-induced and anthracycline-associated cardiac damage
Ann. Onc., September 1, 2002; 13(9): 1331 - 1339.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L.C.M. Kremer, M.M.C. Tiel-van Buul, M.C. Ubbink, M. Offringa, J. Ottenkamp, R. V. Olmos, and P.A. Voute
Indium-111-Antimyosin Scintigraphy in the Early Detection of Heart Damage After Anthracycline Therapy in Children
J. Clin. Oncol., April 1, 1999; 17(4): 1208 - 1208.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.